Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
2(33%)
Results Posted
0%(0 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
5
83%
Ph phase_2
1
17%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(1)
Terminated(3)

Detailed Status

Terminated2
Recruiting2
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

completed117%
terminated233%
withdrawn117%
recruiting233%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_2

Open-Label Extension Protocol to SNK01-AD01 Study

NCT07228078
recruitingphase_1

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

NCT06189963
terminatedphase_1

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

NCT05099549
terminatedphase_1

Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

NCT04678453
completedphase_1

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

NCT03941262
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07228078Phase 2

Open-Label Extension Protocol to SNK01-AD01 Study

Recruiting
NCT06189963Phase 1

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

Recruiting
NCT05099549Phase 1

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Terminated
NCT04678453Phase 1

Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

Terminated
NCT03941262Phase 1

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Completed
NCT04464967Phase 1

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6